Triple-negative breast cancers (TNBCs), described as breast cancers negative for progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2), constitute about 15–20% of breast cancer cases. This evidence concerns the gene PGR and breast carcinoma.